<?xml version='1.0' encoding='utf-8'?>
<document id="21281203"><sentence text="Evaluation of an extractionless high-performance liquid chromatography-tandem mass spectrometry method for detection and quantitation of rosiglitazone in canine plasma."><entity charOffset="137-150" id="DDI-PubMed.21281203.s1.e0" text="rosiglitazone" /></sentence><sentence text="To develop a simple extractionless method for detection of rosiglitazone in canine plasma and test the method in a pharmacokinetic study after oral administration of rosiglitazone in dogs"><entity charOffset="59-72" id="DDI-PubMed.21281203.s2.e0" text="rosiglitazone" /><entity charOffset="166-179" id="DDI-PubMed.21281203.s2.e1" text="rosiglitazone" /><pair ddi="false" e1="DDI-PubMed.21281203.s2.e0" e2="DDI-PubMed.21281203.s2.e0" /><pair ddi="false" e1="DDI-PubMed.21281203.s2.e0" e2="DDI-PubMed.21281203.s2.e1" /></sentence><sentence text="" /><sentence text="3 client-owned dogs with cancer" /><sentence text="" /><sentence text="High-performance liquid chromatography-tandem mass spectrometry was performed on canine plasma" /><sentence text=" The 3 dogs with cancer in the pharmacokinetic study were assessed via physical examination and clinicopathologic evaluation and considered otherwise healthy" /><sentence text=" Food was withheld for 12 hours, and dogs were administered a single dose (4 mg/m²) of rosiglitazone"><entity charOffset="87-100" id="DDI-PubMed.21281203.s8.e0" text="rosiglitazone" /></sentence><sentence text=" Plasma was collected at various times, processed, and analyzed for rosiglitazone"><entity charOffset="68-81" id="DDI-PubMed.21281203.s9.e0" text="rosiglitazone" /></sentence><sentence text="" /><sentence text="The developed method was robust and detected a minimum of 0" /><sentence text="3 ng of rosiglitazone/mL"><entity charOffset="8-21" id="DDI-PubMed.21281203.s12.e0" text="rosiglitazone" /></sentence><sentence text=" Mean ± SD maximum plasma concentration was 205" /><sentence text="2 ± 79" /><sentence text="1 ng/mL, which occurred at 3 ± 1 hours, and mean ± SD elimination half-life was 1" /><sentence text="4 ± 0" /><sentence text="4 hours" /><sentence text=" The area under the plasma rosiglitazone concentration-versus-time curve varied widely among the 3 dogs (mean ± SD, 652"><entity charOffset="27-40" id="DDI-PubMed.21281203.s18.e0" text="rosiglitazone" /></sentence><sentence text="2 ± 351" /><sentence text="3 ng/h/mL)" /><sentence text="" /><sentence text="A simple extractionless method for detection of rosiglitazone in canine plasma was developed and was validated with excellent sensitivity, accuracy, precision, and recovery"><entity charOffset="48-61" id="DDI-PubMed.21281203.s22.e0" text="rosiglitazone" /></sentence><sentence text=" The method enabled unambiguous evaluation and quantitation of rosiglitazone in canine plasma"><entity charOffset="63-76" id="DDI-PubMed.21281203.s23.e0" text="rosiglitazone" /></sentence><sentence text=" This method will be useful for pharmacokinetic, bioavailability, or drug-drug interaction studies" /><sentence text=" Oral rosiglitazone administration was well tolerated in the dogs"><entity charOffset="6-19" id="DDI-PubMed.21281203.s25.e0" text="rosiglitazone" /></sentence><sentence text="" /></document>